 Connection
Ping-Ching Hsu to Antineoplastic Agents
This is a "connection" page, showing publications Ping-Ching Hsu has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.271 |
|
|
|
-
Hsu PC, Chang JW, Chiu LC, Yang CT, Kuo SC, Fang YF, Wu CE. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clin Transl Oncol. 2025 May; 27(5):1967-1979.
Score: 0.123
-
Lu CW, Wang TY, Yen CF, Chen KH, Wu CE, Wang CL, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Lin YJ, Chen MJ, Chen CB, Su Pang JH, Chung WH, Ko YS. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. Int J Dermatol. 2021 Feb; 60(2):179-184.
Score: 0.093
-
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity. J Allergy Clin Immunol Pract. 2025 Jan; 13(1):143-154.e10.
Score: 0.031
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|